alexa T Cell Immunogen Discovery And Design For HIV
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs
June 19-20, 2017 London, UK

Edward McGowan
IAVI, London, UK
ScientificTracks Abstracts: J AIDS Clin Res
DOI: 10.4172/2155-6113-C1-017
HIV remains a significant global health burden and an effective vaccine remains a goal. During infection, control is mediated by a Tcell response and a vaccine will need to induce these cells. HIV has extreme sequence diversity, however, selection pressures at the transmission event restrict this. Consequentially, we are identifying viruses with an estimated date of infection of less than 60 days, from HIV infection cohorts allowing characterisation of the Transmitted Founder Virus. Diversity is assessed for sequence and function, ensuring broad sequence and phenotypic coverage. A further issue when designing a T-cell mediated immunogen is the diversity of the HLA. In order to restrict this impact, modelling is performed, allowing definition of potential epitopes with breadth and coverage. These epitopes are produced as peptides allowing assessment of specific responses in individuals who are effectively controlling virus. The information is collated and viruses which best reflect diversity and modelled peptides are selected for inclusion in a virus panel for functional assessment of T cell responses. By identifying regions of the virus most susceptible to immune control at the point of transmission, that we will use to generate a mosaic vaccine insert.

Edward McGowan currently working as the Scientific Director of the International AIDS Vaccine Initiative (IAVI) sponsored Human Immunology Laboratory (HIL) at Imperial College in London. Edward have approximately 15 years of experience as an Immunologist, the first 9 of which were spent working on vaccine adjuvant design studies where he investigated both arms of the adaptive immune response and innate immunity with a particular focus to mechanisms of Dendritic Cell activation. Since 2015 Edward working as Scientific Director at the HIL.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version